HER2/neu in tissue; HER2/Neu (erbB2) protein expression (H2N Oncosite)
Jump to navigation
Jump to search
Pathology
- overexpression of HER2 (at protein level) in 25% of breast cancer
- overexpression predicts more aggressive disease
Indications
Laboratory
- ~20% of tests for HER2 protein expression
- LOINC: 18474-7, 31150-6, 32996-1, 42914-2, 48675-3, 48676-1, 49683-6, 51981-9
Methods
More general terms
More specific terms
Additional terms
References
- ↑ The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2010) 2010 National Comprehensive Cancer Network, Inc.
- ↑ Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17159189 Corresponding NGC guideline withdrawn Dec 2012
- ↑ ARUOP consult: ERBB2 (HER2/neu) (HercepTest) Testing https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing
HercepTest Tissue Assay, Paraffin Laboratory Test Directory ARUP: http://www.aruplab.com/guides/ug/tests/0049174.jsp - ↑ Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013 Nov 1; 31:3997 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24101045 <Internet> http://jco.ascopubs.org/content/31/31/3997